Sutro Biopharma
STRO
87 hedge funds and large institutions have $46.4M invested in Sutro Biopharma in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 22 closing their positions.
17% more capital invested
Capital invested by funds: $39.6M → $46.4M (+$6.72M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.28% less ownership
Funds ownership: 6.58% → 6.3% (-0.28%)
12% less funds holding
Funds holding: 99 → 87 (-12)
39% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 33
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$435K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$379K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$295K |
| 4 |
Two Sigma Investments
New York
|
+$240K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$560K |
| 2 |
Jane Street
New York
|
-$492K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$368K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$367K |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$357K |
STRO Hedge Fund Activity: Q3 2025 in Review
87 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2025, worth a combined $46.4M — up 17% from $39.6M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of STRO and 10 opened new positions — a net loss of 12 holders — while 33 trimmed existing stakes and 20 added.
The largest buyer was Renaissance Technologies, adding an estimated $435K. The largest seller was AQR Capital Management, cutting an estimated $560K.
- 87 institutional investors held Sutro Biopharma (STRO) as of Q3 2025, down from 99 in Q2 2025.
- Funds reported $46.4M of Sutro Biopharma stock for Q3 2025, up 17% quarter-over-quarter.
- 10 funds opened new Sutro Biopharma positions in Q3 2025 and 22 closed out, a net change of -12 holders.
- The largest Sutro Biopharma buyer in Q3 2025 was Renaissance Technologies, an estimated $435K added.
- The largest Sutro Biopharma seller in Q3 2025 was AQR Capital Management, an estimated $560K sold.
Based on aggregated 13F filings for Q3 2025.